Sign In
Buy CSTL
$24.69
-0.795 (-3.12%)
At Close: Jul 24, 2026
Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin
07:00am, Friday, 11'th Oct 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will sponsor the 71st Annual Montagna Symposium on the Biology of the Skin, hosted by the OHSU Dept of Dermatology, being held
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #2024SMRCongress--Castle will present new data on DecisionDx-Melanoma and DecisionDx-UM at the 21st International Congress of the Society for Melanoma Res
Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's What You Should Know
01:05pm, Monday, 07'th Oct 2024
Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
07:00am, Wednesday, 02'nd Oct 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--The company will hold a groundbreaking ceremony Oct. 22 to celebrate the recent construction start of its new corporate campus and off
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASTRO--Castle will share data at ASTRO24 showing its DecisionDx-SCC test can provide impactful risk stratification in high-risk SCC patient sub-populatio
Castle Biosciences: Inflection Into Profitability
06:41am, Friday, 16'th Aug 2024
Castle Biosciences is a fast-growing molecular diagnostics company with a focus on prognostic tests for cancer and mental health patients. The company inflected into net income and operating profitabi
Castle Biosciences, Inc. (CSTL) Q2 2024 Earnings Call Transcript
10:35pm, Monday, 05'th Aug 2024
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR & Corporate Affairs Derek Maetzold - Founder, President
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates
06:46pm, Monday, 05'th Aug 2024
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to loss of $0.70 per share a year
Castle Biosciences Reports Second Quarter 2024 Results
04:05pm, Monday, 05'th Aug 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL) today announced its financial results for the second quarter and six months ended June 30, 2024.
Will Castle Biosciences, Inc. (CSTL) Report Negative Earnings Next Week? What You Should Know
11:06am, Monday, 29'th Jul 2024
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma
07:00am, Monday, 22'nd Jul 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences and skin cancer survivor Teddi Mellencamp Arroyave launch campaign aimed at empowering patients impacted by melanoma.
All You Need to Know About Castle Biosciences (CSTL) Rating Upgrade to Strong Buy
01:01pm, Friday, 12'th Jul 2024
Castle Biosciences (CSTL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Castle Biosciences Honored with Top Workplaces Awards
07:00am, Thursday, 11'th Jul 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle honored as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Exce
Top 5 Health Care Stocks That May Explode In July
08:40am, Monday, 08'th Jul 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AGA--The latest AGA clinical practice guideline acknowledges the role that TissueCypher can play identifying high-risk Barrett's esophagus patients.
